FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden 0.5 hours per response

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* RASTETTER WILLIAM H						2. Issuer Name and Ticker or Trading Symbol BIOGEN IDEC INC [BIIB]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
(Last)		First) (Middle)				3. Date of Earliest Transaction (Month/Day/Year) 02/15/2005								X	Officer (below)	Officer (give title below) Executive Chairman			
(Street) CAMBRIDGE MA 02142					4.	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Ind Line)	Form filed by More than One Reporting				1
(City)	(5	State)	(Zip)											Person					
		Та	ıble I - N	on-De	rivati	ve S	ecur	ities Ac	quire	d, Di	sposed o	of, or Be	nefi	cially	Owned				
			Date	2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a				5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)	Pric	е	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)
Common Stock 0					02/15/2005				M		120,313	B A	\$3	.3542	120	,313	D		
Common Stock				02/1	02/15/2005				S ⁽¹⁾		2,500	D	\$67.51		117	,813	Г		
Common Stock				02/15/2005		5			S ⁽¹⁾		27,500	D	D \$67.56		90,313		Г		
Common Stock				02/15/2005		5			S ⁽¹⁾		22,500	D \$67.6		7 .624 3	67,813		D		
Common Stock				02/1	02/15/2005				S ⁽¹⁾		7,500	00 D \$		67.69	60,313		D		
Common Stock				02/1	02/15/2005				S ⁽¹⁾		5,000	D	\$(\$67.79		5,313			
Common Stock 05				02/1	02/15/2005				S ⁽¹⁾		10,000	D	\$(57.86	45,	45,313			
Common Stock 02/15/2				5/200	2005					32,500	D	\$(67.87	12,	12,313				
Common Stock 02/15/				5/200	2005			S ⁽¹⁾		7,500	D	\$67.8724		5,313		D			
Common Stock 02/15				5/200	2005					5,313	D	\$(57.91	0		D			
Common Stock														371,	629 ⁽²⁾	I	1	by Trust	
Common Stock														50,67	76.77 ⁽³⁾				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemi Execution if any (Month/Da	Date,	4. Transaction Code (Instr. 8)		n Derivative		6. Date Exerci Expiration Da (Month/Day/Y		ite	7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		D	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securitie Beneficia Owned Following Reported Transacti	e O s Fe ally D or g (I)	0. wnership orm: irect (D) r Indirect) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(A) (D)	Date Exercis	able	Expiration Date	Title	Amo or Num of Si		(Instr.		(>)		
Stock Option (right-to- buy) ⁽⁴⁾	\$3.3542	02/15/2005			M			120,313	(5)		01/24/2006	Common Stock	120	,313	(4)		D		

Explanation of Responses:

- $1. \ Sale\ pursuant\ to\ a\ trading\ plan\ intended\ to\ comply\ with\ Rule\ 10b5-1\ of\ the\ Securities\ Exchange\ Act\ of\ 1934.$
- 2. Increase in the amount of indirectly held shares is the result of a transfer of directly held shares into a trust.
- 3. Decrease in the amount of directly held shares is the result of a transfer of directly held shares into a trust.
- 4. Granted under one of the Issuer's stock option plans, in an exempt transaction under SEC rule 16(b)-3(d).
- 5. Option became exercisable as to 25% of the optioned shares on 1/25/96 and as to the balance of the shares in 36 equal monthly installments thereafter.

Remarks:

By: Benjamin S. Harshbarger; For: William H. Rastetter

02/17/2005

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Know all by these presents, that the undersigned's hereby makes, constitutes and appoints Thomas J. Bucknum, Anne Marie Cook, Benjamin S. Harshbarger, Jo Ann Taormina and Kevin M. Foley as the undersigned's true and lawful attorney-in-fact, with full power and authority as hereinafter described on behalf of and in the name, place and stead of the undersigned to:

- (1) prepare, execute, acknowledge, deliver and file Forms 3, 4, and 5 (including any amendments thereto) with respect to the securities of Biogen Idec Inc., a Delaware corporation (the "Company"), with the United States Securities and Exchange Commission, any national securities exchanges and the Company, as considered necessary or advisable under Section 16(a) of the Securities Exchange Act of 1934 and the rules and regulations promulgated thereunder, as amended from time to time (the "Exchange Act");
- (2) seek or obtain, as the undersigned's representative and on the undersigned's behalf, information on transactions in the Company's securities from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to the undersigned and approves and ratifies any such release of information; and
- (3) perform any and all other acts which in the discretion of such attorney-in-fact are necessary or desirable for and on behalf of the undersigned in connection with the foregoing.

The undersigned acknowledges that:

- (1) this Power of Attorney authorizes, but does not require, such attorney-in-fact to act in their discretion on information provided to such attorney-in-fact without independent verification of such information;
- (2) any documents prepared and/or executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney will be in such form and will contain such information and disclosure as such attorney-in-fact, in his or her discretion, deems necessary or desirable;
- (3) neither the Company nor such attorney-in-fact assumes (i) any liability for the undersigned's responsibility to comply with the requirement of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements, or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act; and
- (4) this Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned's obligations under the Exchange Act, including without limitation the reporting requirements under Section 16 of the Exchange Act.

The undersigned hereby gives and grants the foregoing attorney-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary or appropriate to be done in and about the foregoing matters as fully to all intents and purposes as the undersigned might or could do if present, hereby ratifying all that such attorney-in-fact of, for and on behalf of the undersigned, shall lawfully do or cause to be done by virtue of this Limited Power of Attorney.

This Power of Attorney shall remain in full force and effect until revoked by the undersigned in a signed writing delivered to such attorney-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 1st day of February, 2005.

William H. Rastetter